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Splice switchingCell-penetrating peptides (CPPs) are membrane permeable vectors recognized for their intrinsic ability to
gain access to the cell interior. The hydrophobic counter-anion, pyrenebutyrate, enhances cellular uptake of
oligoarginine CPPs. To elucidate CPP uptake mechanisms, the effect of pyrenebutyrate on well-recognized
CPPs with varying hydrophobicity and arginine content is investigated. The cellular CPP uptake and CPP-
mediated oligonucleotide delivery is analyzed by ﬂuorescence activated cell sorting, confocal microscopy,
and a cell-based splice-switching assay. The splice-switching oligonucleotide is a mixmer of 2′-O-methyl
RNA and locked nucleic acids delivered as a non-covalent complex with 10-fold molar CPP excess. CPP-
induced membrane perturbation on large unilamellar vesicles is investigated in calcein release experiments.
We observed that pyrenebutyrate facilitates cellular uptake and translocation of oligonucleotide mediated by
oligoarginine nonamer while limited effect of pyrenebutyrate on more hydrophobic CPPs was observed. By
combining the different experimental results we conclude that the pathway for cellular uptake of
oligoarginine is dominated by direct membrane translocation, whereas the pathway for oligoarginine-
mediated oligonucleotide translocation is dominated by endocytosis. Both mechanisms are promoted by
pyrenebutyrate and we suggest that pyrenebutyrate has different sites of action for the two uptake and
translocation mechanisms.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Cell-penetrating peptides (CPPs) are relatively short peptides,
mainly cationic, with the ability to penetrate through biological
membranes and gain access to the intracellular environment. These
peptides share a distinguishing characteristic to also deliver various
cargo molecules, such as proteins and oligonucleotides (ONs), into
cells, making them highly interesting for drug delivery [1]. Direct
energy-independent penetration has been suggested as uptake
mechanism for some CPPs [2,3] while endocytosis is the proposed
dominating uptake mechanism for most CPPs, implying that endoso-
mal release inﬂuences translocation [4,5]. Several CPPs are rich in
arginine residues and the number of arginine residues seems to be anbutyrate, 4-(1-pyrenyl)-buty-
palmitoyl-2-oleoyl-phosphati-
rol; ON, oligonucleotide; LNA,
large unilamellar vesicle; R9,
sportan 10; pVEC, vascular
46 8 16 13 71.
tam).
ll rights reserved.important factor for cellular uptake [6,7]. This is substantiated by the
fact that oligoarginines have proven to be efﬁcient CPPs [8,9].
However, the efﬁcient CPP transportan 10 (TP10) has no arginine
residues in the sequence [10].
For oligoarginines, the ability to cross lipid bilayers and gain access
to the cell interior is enhanced in the presence of the hydrophobic
counter-anion 4-(1-pyrenyl)-butyric acid (pyrenebutyrate) [3,11,12].
It has been proposed that electrostatic interactions between peptide
and pyrenebutyrate increase the hydrophobicity of the hydrophilic
oligoarginine, facilitating cellular uptake and translocation [3,11].
Here, cellular uptake is deﬁned as the accumulation of the CPP and
potentially associated cargo within the cell, irrespectively of its
intracellular localization and translocation is deﬁned as direct access
to non-vesicular compartments, e.g., cytosol and/or nucleus [13].
The guanidinium head group of arginine enables bidentate
hydrogen bonding, which most likely is the explanation for the
higher octanol/water partition coefﬁcient registered for oligoarginine
than for corresponding ornithine oligomers in the presence of
hydrophobic counter-anions [14] as well as oligoarginine partition
in chloroform in the presence of phosphatidylglycerol [15]. It has been
proposed that the ability of guanidinium groups to form bidentate
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2510 P. Guterstam et al. / Biochimica et Biophysica Acta 1788 (2009) 2509–2517hydrogen bonds is important for formation of ion pair complexes
with, for example, the carboxyl of pyrenebutyrate or with phospho-
lipids [12,14,15]. Complexes of pyrenebutyrate and oligoarginines can
result in addition of hydrophobicity to the hydrophilic oligoarginine
peptide, and thereby increase the potential of the peptide to interact
with lipid bilayers [16]. Pre-treating cells with pyrenebutyrate before
oligoarginine exposure increases cellular uptake as compared to non-
pre-treated cells. This observation indicates the positive effect of
pyrenebutyrate on membrane permeation for oligoarginine CPPs and
could, possibly, facilitate translocation of oligoarginine associated
cargo molecules [3,11].
The effect of the hydrophobic counter-anion pyrenebutyrate on
cellular CPP uptake has, so far, mainly been studied for oligoargi-
nine and not, in detail, for other CPPs [3]. To delineate the
mechanisms for cellular uptake and translocation of CPPs we have
in this study selected a number of previously characterized CPPs in
addition to oligoarginine. These peptides have distinctly different
hydrophobic properties and number of arginine residues. We
assessed the impact of pyrenebutyrate on their capacity to gain
intracellular access and by an ON cargo to give rise to biological
activity. We investigate the effect of pyrenebutyrate on live cells
with ﬂuorescently labeled peptides utilizing ﬂuorescence activated
cells sorting (FACS) and confocal microscopy to quantify cellular
uptake of the peptides. A cell-based splice-switching reporter assay
was used to examine the effect of pyrenebutyrate on CPP-mediated
translocation of bioactive phosphorothioate 12-mer ON with 2′-O-
methyl RNA (2OMe) and locked nucleic acid (LNA) monomers, so
called mixmer. The ONs were delivered to cells as non-covalent
complexes with CPPs at a CPP:ON molar ratio of 10:1. By using
bioactive cargoes, the cargo delivery to intracellular targets can be
assessed [16]. To gain further insight into the effects of pyrenebu-
tyrate on phospholipid membranes, we determined CPP- and
pyrenebutyrate-induced model membrane perturbation, by studies
of calcein release from uncharged 1-palmitoyl-2-oleoyl-phosphati-
dylcholine (POPC) and partly charged POPC/1-palmitoyl-2-oleoyl-
phosphatidylglycerol (POPG) (70/30) large unilamellar vesicles
(LUVs). The LUV experiments show that cellular uptake of CPPs
differs from the ability for interaction with LUV membranes, and
indicate that speciﬁc cellular structures and/or biological mechan-
isms are involved in the uptake of CPPs into live cells. However, the
number of arginine residues and the overall hydrophobicity of a
CPP do inﬂuence the impact that pyrenebutyrate has on its uptake
and translocation into cells. This gives insights regarding the crucial
properties needed for cellular delivery and opens for design of
further optimized CPPs.Ta
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.2. Materials and methods
2.1. Oligonucleotides and peptides
Phosphorothioate 2OMe ONs, with and without 5′-linked Cy5
label, were synthesized on an ÄKTA™ oligopilot™ plus 10 synthesizer
(GE Healthcare) as previously described [17,18]. The 2OMe/LNA
mixmers were obtained from RiboTask.
FITC (ﬂourescein isothiocyanate) labeled peptides used for FACS
and confocal microscopy were chemically synthesized by Fmoc (9-
ﬂuorenylmethyloxycarbonyl) solid-phase peptide synthesis (SPPS)
to have a γ-aminobutyric acid (GABA) residue as linker to N-
terminally attached FITC to the peptides as previously reported [19].
Non-labeled peptides used for the splice-switching experiments
were synthesized using t-Boc (di-tert-butyl dicarbonate) SPPS and
puriﬁed by reversed phase HPLC as previously described [17].
Average hydrophobicity, for peptides without label or cargo, is
calculated utilizing the von Heijne scale for biological hydrophobi-
city (Table 1) [20].
2511P. Guterstam et al. / Biochimica et Biophysica Acta 1788 (2009) 2509–25172.2. Confocal microscopy
HeLa cells (200,000) were plated into 35-mm glass-bottomed
dishes (Iwaki) and cultured for 48 h. After removing the medium,
the cells were washed twice with phosphate buffered saline (PBS)
supplemented with 100 mg/ml CaCl2 and 100 mg/ml MgCl2 × 6H20
(PBS(+)). In the cellular CPP uptake experiments (Fig. 1), the cells
were ﬁrst incubated with pyrenebutyrate in PBS(+) for 5 min, and
then the peptide solution in PBS(+) (40 μM) was added to yield the
ﬁnal concentration of pyrenebutyrate and peptides (50 and 10 μM,
respectively). After incubation for 15 min, the cells were washed
with PBS(+). The localization of the ﬂuorescently labeled peptides
was analyzed without ﬁxing using a confocal scanning laser
microscope (Olympus FV300) equipped with a 40× objective lens
(UplanApo, NA 0.85).
In the cellular CPP-mediated ON uptake experiments (Fig. 8), HeLa
cells were washed twice with PBS(+), treated with 50 μM pyrene-
butyrate in PBS(+) for 1 min, and thereafter the cells were washed
twice with PBS(+). Then 150 μl PBS(+) was added to cells followed
by immediate addition of 50 μl of non-covalent CPP–ON complexes at
ﬁnal 5 μM CPP concentration and 500 nM ON concentration and
chloroquine diphosphate at 75 μM concentration. The mixture of CPP
and ON was prepared by mixing CPP and ON in PBS(+) at room
temperature for 30min, followed by addition of chloroquine. The cells
were then incubated at 37 °C for 1 h, washed with PBS(+), and then
incubated with for 16 h in alpha-MEM containing 10% fetal bovine
serum. The localization of FITC-labeled R9 and Cy5-ON was analyzed
without ﬁxing using a confocal scanning laser microscope (Olympus
FV1000) equipped with a 40× objective lens (UplanSApo, NA 0.95).
2.3. Quantiﬁcation of peptide uptake
HeLa cells were pre-incubated at 37 °C with pyrenebutyrate
(50 μM) in PBS(+) for 5 min prior to the addition of FITC-labeled CPPs
(10 μM) in PBS(+). After 15-min incubation, the cells were washed
twice with PBS containing 0.5 mg/ml heparin, and then treated with
0.01% trypsin in PBS at 37 °C for 10 min. The cells were centrifuged at
3000 rpm (600 g) for 5 min. The supernatant was removed; the cells
werewashedwith PBS and centrifuged at 3000 rpm for another 5min.
The supernatant was removed; the cells were washed with PBS and
centrifuged at 3000 rpm for 5 min. After this washing cycle was
repeated, the cells were suspended in PBS (400 μl) and subjectedFig. 1.Observations of cellular uptake by confocal microscopy. Uptake of FITC-labeled CPPs in
peptide for 15 min with or without 5-min pre-treatment of 50 μM pyrenebutyrate (PB) beftoﬂuorescence analysis onaFACSCaliburﬂowcytometer (BDBioscience)
using a 488 nm laser excitation and a 515–545 nm emission ﬁlter. Each
sample was analyzed for 10,000 events.
2.4. Preparation of large unilamellar vesicles
Large unilamellar vesicles with POPC (Avanti Polar Lipids) and
optionally 30% POPG (Avanti Polar Lipids) were prepared by
dissolving the lipid, without further puriﬁcation, at the desired
concentration in chloroform to obtain a homogeneous solution of
the lipid and then the solvent was removed by evaporating it under
high vacuum for 3 h. The resulting dried lipid ﬁlm was re-suspended
by adding 50 mM potassium phosphate buffer solution (pH 7.4). This
solution was then vortexed for 10 min followed by ﬁve freeze–thaw
cycles to reduce the lamellarity. After the freezing and thawing cycles,
the lipid solution was pushed through two polycarbonate ﬁlters
(100 nm pore size) 20 times by using an Avanti manual extruder. This
method gave unilamellar vesicles with 100 nm diameter.
2.5. Calcein release from large unilamellar vesicles
LUVs with entrapped calcein (C30H26N2O13, 622.5 Da, Molecular
Probes) were prepared by using a buffer solution containing 55 mM
calcein with the above mentioned method. The ﬁnal pH was adjusted
to 7.4. Free calcein outside the vesicles was removed by passing
through Sephadex-G25 (GE Healthcare) columns two times. The
ﬂuorescence intensity of calcein was recorded on a Horiba Jobin Yvon
Fluorolog-3 spectroﬂuorometer using a 490 nm laser excitation and a
510 nm emission ﬁlter. The ﬂuorescence intensity in the presence of
55 mM calcein is low due to self-quenching, but increases upon
dilution. Pyrenebutyrate with the ﬁnal concentration of 50 μM was
added to the vesicle solution composed of 100 μM POPC or POPC/
POPG (70/30). Each CPP was ﬁrst titrated to the LUVs to deﬁne a
suitable treatment concentration that induces observable calcein
release without the presence of pyrenebutyrate. It was found that a
concentration of 5 μM was suitable for all investigated CPPs, except
TP10 where it was 0.01 μM. The CPPs were applied to LUVs after 10-
min pyrenebutyrate pre-treatment at 20 °C. The release of calcein was
monitored as an increase in the ﬂuorescence intensity at various
peptide incubation time points. One hundred percent calcein release
was induced by the addition of 10% (w/v) Triton X-100 (Sigma-
Aldrich). Using this as a reference and by subtracting the backgroundlive HeLa cells as analyzed by confocal microscopy. HeLa cells were exposed for 10 μMof
ore addition of peptide.
Fig. 2. Quantiﬁcation of cellular uptake by ﬂuorescence assisted cell sorting.
Quantiﬁcation of uptake of FITC-labeled CPPs in live HeLa cells as analyzed by FACS.
HeLa cells were exposed for 10 μM of peptide for 15 min with or without 5-min pre-
treatment of 50 μM pyrenebutyrate (PB) before addition of peptide. The FACS data are
presented as normalized cellular uptake for pyrenebutyrate pre-treated cells as
compared to non-pre-treated cells. Cytotoxicity was observed for TP10.
2512 P. Guterstam et al. / Biochimica et Biophysica Acta 1788 (2009) 2509–2517ﬂuorescence, the degree of calcein release induced by different
peptides was calculated using the following equation: % calcein
release=[(F − F0)/(Fr − F0)]×100, where F0 and Fr are the initial
ﬂuorescence intensities observedwithout peptide and after treatment
with Triton X-100, respectively. F is the ﬂuorescence intensity in the
presence of peptides. The standard deviation in the endpoints
(10 min) was less than ±4 in units of % calcein release (Fig. S1).
2.6. Splice-switching assay
The day before experiments, 80,000 pLuc705 HeLa cells were
seeded in 24-well plates (Sigma-Aldrich), and grown overnight in
Dulbecco's modiﬁed Eagle medium (DMEM) supplemented with
0.1 mM non-essential amino acids, 1.0 mM sodium pyruvate, and 10%
(v/v) fetal bovine serum (full media). Cells were washed with PBS
(Invitrogen), treated with 50 μM pyrenebutyrate (Sigma-Aldrich) in
PBS for 1 min, and thereafter the cells were washed two times with
PBS. Then 180 μl PBS was added to cells followed by immediate
addition of 20 μl of CPP and ON complexes with chloroquine
diphosphate (Sigma-Aldrich) giving rise to a ﬁnal treatment con-
centration of 5 μM peptide, 500 nM mixmer, and 75 μM chloroquine.
The transfection mixture was prepared by mixing CPP and ON in PBS
at room temperature 30min prior to addition of chloroquine. The cells
were then incubated at 37 °C for 1 h, washed with PBS, and allowed to
grow for 16 h in DMEM supplemented with 0.1 mM non-essential
amino acids, 1.0 mM sodium pyruvate, and 10% fetal bovine serum
(full growth media).
For transfection of oligonucleotides utilizing Lipofectamine™
2000, the cells were washed with PBS (Invitrogen), and treated for
16 h in 200 μl of transfection mixture. The transfection mixture
consisted of 100 μl of full growth media and 100 μl of DMEM,
oligonucleotide, and Lipofectamine™ 2000 (2.5 μl/μg ON).
The cells were then washed with PBS and lysed using 100 μl of cell
culture lysis buffer (Promega) for 15 min at room temperature.
Luciferase activity in the cell lysate was measured using Glomax™ 96
plate luminometer (Promega). Protein content in the cell lysate was
determined by Lowry-assay (Bio-Rad) and mitochondrial activity was
determined with wst-1 assay (Roche Applied Science) according to
the manufacturer's protocol.
2.7. Statistical analysis
Results are presented as means±standard error of the mean in all
ﬁgures and standard deviation is shownwithin parenthesis in Table 1.
Each splice-switching experiment was performed in triplicate while
each confocal microscopy and cellular uptake experiment was
performed in duplicate. Each POPC and POPC/POPG LUV experiments
were performed as single treatments after initial optimization of
peptide treatment concentration. GraphPad Prism (4.00) was used for
graphs and associated calculations.
3. Results and discussion
3.1. Cell-penetrating peptides
Most CPPs are cationic and arginine residues or, more speciﬁcally,
guanidinium groups are often important for activity. Guidelines for
CPP design have been proposed but universally applicable rules are
lacking [21]. The use of pyrenebutyrate as counter-anion to CPPs
should add hydrophobic properties to hydrophilic peptides and
thereby it increases the ability for insertion into lipid bilayers. Here,
CPPs with distinctly dissimilar structures in terms of amino acid
residue composition, sequence length, and hydrophobic properties
have been selected for investigation of the inﬂuence of pyrenebuty-
rate on cellular uptake and translocation capacity (Table 1). The CPPs
selected are the hydrophilic oligoarginine nonamer, R9 [8], and theHIV-1 transactivator of transcription derived peptide, pTat48–60
[22,23]. Intermediately hydrophobic CPPs [24] selected are penetratin
(Pen) derived from the Antennapedia protein [2], M918 derived from
the tumor suppressor protein p14ARF [25], and pVEC derived from the
cell adhesion molecule vascular endothelial cadherin [26]. The most
hydrophobic peptide examined, TP10, has no arginine residues and it
is the only CPP in this selection that has been assigned to be taken up
by clathrin-mediated endocytosis [10,27]. To reveal the impact of
arginine residues for ON delivery and lipid bilayer interactionwe have
also included a penetratin analogous peptide, PenArg, in which all
lysine residues are replaced by arginine residues [7]. The CPPs
included in this study can be divided into three subgroups:
hydrophilic (R9 and pTat48–60), intermediately hydrophobic (Pen,
PenArg, pVEC, and M918), and hydrophobic (TP10) (Table 1). The
CPPs also display different arginine content. The CPPs have been
studied for two biological assay endpoints, namely, the cellular uptake
of FITC-labeled CPPs and the splice-switching assay, and one chemical
assay endpoint, calcein release from LUVs, and the effect of
pyrenebutyrate on these three endpoints.
3.2. Cellular uptake of ﬂuorescently labeled CPPs
The FITC-labeled CPPs were capable of crossing the cellular
membrane of HeLa cells as seen by confocal microscopy and FACS
(Figs. 1 and 2 and Table 1). The peptides with high hydrophobicity
were virtually unaffected by the presence of the pyrenebutyrate
counter-anion while the uptake of more hydrophilic peptides, R9 and
possibly pTat48–60, increased in the presence of and after pre-
treatment with pyrenebutyrate (Fig. 2 and Table 1). The CPP
treatments were performed at 10 μM concentration for 15 min after
5-min pre-treatmentwith only pyrenebutyrate (50 μM). In agreement
with an earlier report, the utilized treatment, including pyrenebuty-
rate, does not induce neither acute leakage nor long-term alterations
in cell viability for R9 [3]. Despite the relatively short treatment time
the hydrophobic peptide TP10 gave rise to cytotoxicity as observed by
microscopy while cells treated with the other CPPs included in the
study induced no or minor toxic effects.
In the presence of 50 μM pyrenebutyrate the cellular uptake was
most prominently enhanced for R9. A most likely explanation is that
pyrenebutyrate inserts into the plasma membrane as previously
reported [11] and thereafter interacts electrostatically by bidentate
hydrogen bonding with the arginine residues during the CPP
treatment, inducing direct translocation. The pTat48–60 CPP has an
overall low cellular uptake but the uptake tends to increase in the
presence of pyrenebutyrate (Fig. 2 and Table 1). Analysis with
2513P. Guterstam et al. / Biochimica et Biophysica Acta 1788 (2009) 2509–2517confocal microscopy reveals that the intracellular CPP-distribution is
diffuse for the hydrophilic peptides and to some extent also for the
intermediately hydrophobic CPPs in the presence of 50 μM pyrene-
butyrate (Fig. 1). Diffuse intracellular distribution is a characteristic
indicative for non-endosomal uptake. In contrast, the hydrophobic
peptide, TP10 without arginine residues, shows a more punctate
distribution, a phenomenon characteristic for endosomal uptake
[19,28] (Fig. 1). The diffuse cellular distribution of the other CPPs
does not prove that direct translocation is the exclusive uptake route,
although it has been conﬁrmed for R9 that pyrenebutyrate assisted
uptake occurs at 4 °C [3]. Rapid endosomal uptake followed by
endosomal release may also result in diffuse cytosolic distribution of
the ﬂuorescently labeled CPPs. However, direct penetration aided by
presence of pyrenebutyrate (50 μM) appears to dominate the cellular
uptake of the arginine-containing CPPs with a ﬂourescein label as a
covalently attached cargo but a contribution of endosomal uptake of
such CPPs cannot be excluded.
3.3. CPP interaction with large unilamellar vesicles
To investigate whether the effect of pyrenebutyrate is directly
correlated with lipid bilayer interaction, peptide and pyrenebutyrate-
induced efﬂux of calcein from uncharged POPC and partially
negatively charged POPC/POPG (70/30) LUVs was investigated [29].
In the LUV experiments one can assess the CPP-induced translocation
of calcein or membrane perturbation by observing calcein release
from the vesicles [12]. The CPPs were applied to 100 μM of calcein-
loaded LUVs after pyrenebutyrate (50 μM) pre-treatment for 10 min
and the induced calcein release was recorded at various time points. A
peptide treatment concentration of 5 μMwas used for all CPPs except
TP10 which had to be applied at 500 times lower concentration due to
its potent membrane interaction.
A clear increase in calcein release was observed in the presence of
pyrenebutyrate for both neutral and partially negatively charged LUVsFig. 3. Inﬂuence of pyrenebutyrate on interactionwith uncharged POPC LUVs and partially ch
and POPC/POPG LUVs (right) at 100 μM treated with 5 μM CPP after 10-min pre-treatment w
corresponding experiments without pyrenebutyrate pre-treatment (lower panels). The CPP
TP10) inducing observable calcein release in the absence of pyrenebutyrate.treated with the intermediately hydrophobic CPPs M918, pVEC, and
Pen Arg (Fig. 3). For the hydrophilic peptides, calcein release
generated by R9 was clearly enhanced by pyrenebutyrate in the
zwitterionic LUVs (Fig. 3 and Table 1). The hydrophobic counter-anion
had aminor effect on calcein release caused by pTat48–60 (Fig. 3). The
intermediately hydrophobic CPP, Pen, behaved together with R9 in a
different manner for charged and uncharged vesicles. As shown in Fig.
3, we observed signiﬁcant calcein release in the presence of
pyrenebutyrate for the zwitterionic POPC vesicles but not for the
partly charged POPC/POPG vesicles. One possible explanation is that
the partly negatively charged vesicles (POPC/POPG) may compete
with pyrenebutyrate, which diminishes its interaction with the
peptides. There is obviously a very delicate balance between
hydrophobic residues, number of arginine residues, and lipid bilayer
interaction that determines the outcome of the LUV experiments with
zwitterionic POPC and partly charged POPC/POPG (70/30) vesicles.
The observation that the intermediately hydrophobic CPPs induce a
dramatic release of calcein in the presence of pyrenebutyrate may
have potential implication in the development of novel antibiotics.3.4. Delivery of bioactive oligonucleotide
It is assumed that CPP interaction with pyrenebutyrate facilitates
the internalization of R9 [11]. To assess the impact of pyrenebutyrate
for translocation of a bioactive ON cargo, a splice-switching reporter
assay was utilized [30]. The splicing reporter system is based on a
plasmid (pLuc705) carrying a luciferase-coding sequence that is
interrupted by an insertion of intron 2 from β-globin pre-mRNA,
which includes an aberrant splice-site that activates a cryptic splice-
site. Unless the aberrant splice-site is masked by a complementary
ON, the pre-mRNA of luciferase will give rise to expression of non-
functional luciferase. By using HeLa cells which are stably transfected
with pLuc705, it is possible to evaluate cellular delivery of splice-arged POPC/POPG (70/30) LUVs. Time-dependent calcein release from POPC LUVs (left)
ith 50 μM pyrenebutyrate (upper panels). The effect of pyrenebutyrate is visualized by
s were applied 15 s (indicated by arrow) before ﬁrst measurement at 5 μM (0.01 μM for
Fig. 4. Truncated LNA/2OMe mixmer equals activity for full-length 2OMe SSO.
Luciferase activity, normalized to activity induced by the 18-mer 2OMe ON, after
treatment at 250 nM utilizing the Lipofectamine™ 2000 transfection reagent. The
truncated 12-mer LNA/2OMe mixmer displays similar splice-switching activity and
speciﬁcity as the corresponding 18-mer 2OMe SSO. Capitals in the sequence list refer to
2OMe monomers and small letters are LNA monomers. Letters in bold refer to mis-
matches to target pre-mRNA.
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positive read-out for CPP-mediated ON translocation [4].
Including LNAmonomers in an antisense ON increases the melting
temperature of the duplex formed with complementary RNA [31].
Here, we present an optimized 12-mer phosphorothioate 2OMe/LNA
mixmer, with four LNAmonomers, displaying similar splice-switching
properties, in terms of speciﬁcity and potency, as the corresponding
18-mer 2OMe ON (Fig. 4) [17].
By co-incubating the splice-switching mixmer with CPP at ratio
1:10 before addition to the cells, expression of functional luciferase
can be observed [32,33] indicating successful translocation of the
splice-switching mixmer (Fig. 5). The opportunity to deliver the
mixmer as a non-covalent complex with CPPs enables for investiga-
tion of the translocation mechanisms utilizing pyrenebutyrate. Here,
to avoid cytotoxicity caused in the splice-switching assay, the cells
were quickly pre-treated with pyrenebutyrate for 1 min followed by
incomplete PBS wash (2×) before CPP–ON treatment for 1 h. It was
conﬁrmed, by ﬂourometric measurements, that pyrenebutyrate (with
λex=345 nm, λem=376 nm) remained in the cells after the wash
step, while repeated wash steps (5×) removed pyrenebutyrate (Fig.
S2) [3]. The treatment time in the splice-switching assay had to beFig. 5. Inﬂuence of pyrenebutyrate on CPP-mediated delivery of splice-switching
oligonucleotide. Luciferase activity induced by successful delivery of splice-switch-
ing oligonucleotide into pLuc705 HeLa cells exposed to CPP and LNA/2OMe mixmer
complexes. The luciferase activity is presented as normalized luciferase activity for
pyrenebutyrate (PB) pre-treated cells as compared to non-pre-treated pLuc705
HeLa cells.extended from 15 min to 1 h to be able to observe clearly detectable
splice-switching activity induced by the CPP-delivered bioactive
mixmer (Fig. S3). The reason for only pre-treating the cells with
pyrenebutyrate followed by incomplete wash is that presence of
50 μM pyrenebutyrate during the 1-h treatment time induces
cytotoxicity (Fig. S4). By quickly pre-treating the cells with pyrene-
butyrate the counter-anion will probably insert into the plasma
membrane and be accessible for later interaction with the CPP–ON
complexes facilitating cellular uptake. The fact that pyrenebutyrate
can be washed out from the cells almost completely indicates that the
major part of the hydrophobic counter-anion is extracellularly
accessible (Fig. S2).
In accordance with the cellular uptake experiments (Fig. 2), the R9
mediated mixmer translocation was remarkably increased by pyr-
enebutyrate as in the use of other hydrophilic CPPs with a high
proportion of arginine residues, i.e., pTat48–60 and Pen (Fig. 5). The
enhanced splice-switching activity by the use of PenArg over Pen
further supports the importance of arginine residues (Fig. 5).
In the presence of pyrenebutyrate, the translocation of ON-mixmer
in non-covalent complex with R9 is not so efﬁcient and treatment had
therefore to be extended from 15 min to 1 h to be able to observe
clearly detectable splice-switching activity induced by the CPP-
delivered bioactivemixmer (Fig. S3). Since chloroquine, which buffers
intracellular vesicles delaying the lysomal pathway for endosomes,
and thereby facilitates potential endosomal release [34], had to be
added to the CPP–ON complexes just prior to starting the cellular
treatment to get successful delivery of the bioactive mixmer (Fig. 6),
the uptake of non-covalent R9-ON complexes would thus be
accomplished mainly by an endocytotic pathway and not solely by
direct penetration through plasma membranes. Endocytosis is a
slower process than direct translocation which is a plausible
explanation to why the treatment time had to be extended in the
splice-switching assay [35].
No or low effects on cell viability from the treatments were
observed for all CPP:ON complexes examined except for the most
hydrophobic CPP, TP10, as determined by analysis of protein content
(data not shown). The viability, as determined by mitochondrial
activity, was moderately reduced for the intermediately hydrophobic
peptides while more evident effect on viability was observed for TP10
(Fig. 7).
The fact that pyrenebutyrate is soaked into the cellular membrane
before interaction with CPP–ON complexes is probably a substantialFig. 6. Inﬂuence of chloroquine and pyrenebutyrate on R9-mediated delivery of splice-
switching oligonucleotide. Luciferase activity induced by successful delivery of splice-
switching oligonucleotide into pLuc705 HeLa cells exposed to CPP and LNA/2OMe
mixmer complexes. Chloroquine (CQ) buffers endosomes and delays the lysosomal
pathway and is needed for delivery of the bioactive mixmer. Pyrenebutyrate (PB) may
enhance the endosomal release but CQ is needed for mixmer delivery indicating that an
endosomal pathway is exploited in R9-mediated ON delivery. The mixmer is included
in all treatments except ‘untreated.’
Fig. 7. Cell viability after CPP-mediated delivery of splice-switching oligonucleotide.
Cell viability as determined by a mitochondrial activity assay (wst-1) for pLuc705 HeLa
cells exposed to CPP and LNA/2OMemixmer complexes following the same protocol as
for the splice-switching assay including pyrenebutyrate pre-treatment.
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since endocytosis relies on initial invagination of the plasma
membrane [36].
Cellular pre-treatment with pyrenebutyrate clearly ameliorates
both uptake of R9 and R9-mediated translocation of mixmer
inducing splice-switching and subsequent increase in luciferase
activity (Figs. 1, 2, and 5 and Table 1). The mechanism of action
for pyrenebutyrate may have similarity in the two experimental
set-ups but the site of action for the hydrophobic counter-anion
seems to differ. For the arginine-rich CPPs the proposed endocy-
totic pathway in the splice-switching studies is supported by
earlier observations that arginine residues have a capacity to
stimulate endocytosis, or more speciﬁcally macropinocytosis [37].
This would also facilitate endocytotic uptake of ONs that are in
non-covalent complexes with arginine-rich CPPs. The low presence
of pyrenebutyrate in the splice-switching experiments, as com-
pared to the cellular uptake experiments, probably alters the
uptake pathway away from direct penetration. The high impact ofFig. 8. Cellular peptide and oligonucleotide distribution after R9-mediated delivery. Confocal
R9 and Cy5-labeled 2OMe ON in accordance with the protocol for the splice-switching assay
labeled R9, Cy5-labeled ON, and by differential interference contrast. The cells have grow
intracellular ONs indicates endosomal uptake. The endosomal release of ON for the pyrenepyrenebutyrate presence on the R9-mediated ON delivery is
possibly explained by promotion of the translocation through the
endosomal membranes, which seems to be the rate-limiting step
for R9-mediated ON delivery in this experimental set-up in
combination with the delay of endosomes entering the lysosomal
degradation pathway created by the presence of chloroquine. The
impact of pyrenebutyrate on calcein release observed in the POPC
LUV experiments (Fig. 3) is probably sufﬁcient to facilitate
endosomal translocation or release of ON, in complex with R9,
explaining the enhanced splice-switching activity in the presence
of pyrenebutyrate (Figs. 5 and 8). Similar, but less prominent,
enhancement of splice-switching activity was also observed for
pTat48–60 and PenArg, and this was presumably because of
smaller arginine content in these sequences inﬂuencing the
capability for endocytotic entry (Fig. 5 and Table 1).
For the other intermediately hydrophobic CPPs, Pen, pVEC, and
M918, the uptake is also mainly endocytotic since treatment time
had to be extended and chloroquine had to be included in the
CPP–ON transfection mixture to be able to record any splice-
switching activity (data not shown). However, the hydrophobicity
and the relatively low proportion of arginine residues in these
peptides may limit the endocytotic entry and thereby the potential
effect of pyrenebutyrate as an endosomal releaser. Together this
disfavors the ability of pyrenebutyrate to ameliorate the rate of ON
translocation.
The mechanism of uptake for the most hydrophobic CPP TP10 is
outside of the reasoning used for the hydrophilic and the inter-
mediately hydrophobic CPPs investigated here. The TP10 peptide does
not have any arginine residue and its uptake route is clathrin-
mediated endocytosis [27]. Therefore, TP10 neither stimulates
macropinocytosis nor complex formation with pyrenebutyrate, and
this probably explains the very little enhancement of splice-switching
activity by the addition of pyrenebutyrate (Fig. 5 and Table 1). The
result of clathrin-mediated endocytosis is also endocytotic vesicles
and the high hydrophobicity of the peptide per se may outrule the
potential contribution of a hydrophobic counter-anion for endosomal
release.microscopy analysis of HeLa cells treated with non-covalent complexes of FITC-labeled
shows that the ON is taken up by the cells. The same cells have been detected for FITC-
n for 16 h in full growth media after transfection. The vesicular distribution of the
butyrate (PB) pre-treated cells is by no means complete.
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From the present observations we can draw some mechanistic
conclusions. We ﬁrst conclude that the hydrophobic TP10 induces
toxicity in the cellular uptake studies. TP10 exploits a non-arginine
induced endocytotic pathway (clathrin-mediated endocytosis)
[19,27] that is unaffected by pyrenebutyrate (Fig. 5) and TP10 gives
rise to membrane perturbation and associated calcein release from
LUVs at very low peptide concentrations (Fig. 3). This peptide is an
interesting CPP with many potential applications but it displays
deviating properties as compared to the other CPPs in the selection
and it will therefore be excluded from the remaining mechanistic
discussion.
The results suggest distinct patterns of cellular uptake and
translocation mechanisms, varying between the different peptides.
Overall, two major cell entry pathways are considered: the
endosomal pathway composed of two steps, namely, endocytotic
entry followed by endosomal escape, and direct cell membrane
penetration. First we observe that the two biological endpoints in
general go together (Figs. 2 and 5 and Table 1), even though the
effective pyrenebutyrate concentration employed in the cellular
uptake experiments is considerably higher than in the splice-
switching assay.
The LUV calcein release experiments are indicators of the
interaction and perturbation of the lipid membrane caused by the
different CPPs. Release from self-quenching of vesicle enclosed calcein
is commonly used as a measure of bilayer perturbation and
interpreted as “transient pore formation” [38,39]. The present results
on calcein release from LUVs can be used as qualitative indicators of
CPP-related calcein translocation or bilayer perturbation, with
relevance for the direct penetration mode of cell entry, or for the
steps of endosomal membrane translocation or endosomal escape.
Chloroquine acts to some extent in parallel with pyrenebutyrate, in
that it promotes the endosomal escape by prolonging the time it takes
for the endosome to enter the lysosomal pathway, i.e., chloroquine
facilitates the endosomal escape step during the endosomal pathway
[34]. However, there is no evidence that chloroquine promotes the
direct penetration mode of entry.
For the biological endpoints, pyrenebutyrate clearly promotes
the cellular uptake of R9 and R9-mediated ON delivery (Figs. 2 and
5). The other CPPs are less affected by pyrenebutyrate in both
biological assays. For R9, chloroquine is needed to give any splice-
switching activity at all, independent of the absence or presence of
pyrenebutyrate (Fig. 6) indicating that an endosomal pathway is
employed for ON delivery as also observed by confocal microscopy
(Fig. 8). The calcein release from POPC LUVs was to some extent
promoted by pyrenebutyrate for R9 but less extensively than for the
intermediately hydrophobic CPPs Pen, PenArg, pVEC, and M918 (Fig.
3 and Table 1). This suggests also that very little, if any, stable pore
formation or signiﬁcant membrane perturbation may occur for the
translocation of R9.
The suggested interpretation for the hydrophilic and arginine-
rich R9 is that direct penetration is the major pathway for FITC-
labeled R9 peptide itself in the presence of high pyrenebutyrate
concentration (50 μM) (Fig. 1) [3], while the endocytotic pathway,
presumably arginine-induced macropinocytosis, dominates in the
splice-switching assay, i.e., ON translocation mediated by R9 as a
non-covalent complex, where minor amounts of pyrenebutyrate are
present (Fig. 5 and Table 1). In the splice-switching assay the
endosomal escape, from macropinosomes, is rate limiting and this
vesicular release is promoted by pyrenebutyrate (Fig. 5). The
enhanced luciferase activity observed for R9-mediated ON translo-
cation is not reﬂected in analysis with confocal microscopy (Fig. 8).
This can be explained by the fact that the amount of bioactive ON
needed to induce splice-switching activity in the nucleus is very low
[4] and therefore the improved ON-release from endocytoticvesicles observed as enhanced luciferase activity does not have to
be clearly distinguishable by microscopy.
Similar to R9, but less prominent effect of pyrenebutyrate was
observed for the hydrophilic pTat48–60, which also is arginine-rich
but inferior to R9. For pTat48–60, very low cellular uptake was
observed but pyrenebutyrate has a positive effect on the uptake and
gives diffuse cytosolic distribution of the peptide, indicating direct
penetration (Fig. 1). In the splice-switching assay, pyrenebutyrate
yields a smaller enhancement of ON delivery even though the
bioactive mixmer ON is being rather efﬁciently delivered (Fig. 5 and
Table 1). The shift to an endocytotic pathwaymay be due to the longer
treatment time or due to treatment with a non-covalent CPP:ON
complex instead of free peptide. The rate-limiting step in this
experimental set-up is probably the translocation of ON through the
endosomal membranes. The ON is taken up by the cells in non-
covalent complex with R9 into endosomes (Fig. 8) and pyrenebuty-
rate may accelerate the ON translocation into the cytosolic environ-
ment utilizing mechanisms that do not result in extensive, but minor,
membrane perturbation (Fig. 3).
For the intermediately hydrophobic CPPs, Pen, pVEC, and M918,
the biological endpoints are only moderately affected by pyrenebu-
tyrate but calcein release from LUVs is signiﬁcantly enhanced by
pyrenebutyrate (Fig. 3 and Table 1). The rate-limiting step for both
biological endpoints should therefore, in these cases, not be linked to
direct membrane perturbations, neither on the plasmamembrane nor
on endosomes. Since interaction of arginine-rich peptides with
membrane associated proteoglycans has been reported to be critical
for the induction of macropinocytosis [36], increase in hydrophobicity
in arginine-rich peptides might increase in their interaction with
membranes while decreasing its afﬁnity to proteoglycans and this
may eventually result in the decreased endocytotic entry of these
peptides and the accompanied ON. However, further study is
necessary to establish its validity. Delivery of the bioactive ON
mediated by PenArg (Fig. 5 and Table 1), having a higher arginine
density compared to Pen, is more enhanced by pyrenebutyrate, and
this supports the importance of arginine residues in CPPs for effective
cellular uptake and translocation of accompanying ON over endoso-
mal membranes in the presence of pyrenebutyrate.
In summary, the cellular delivery of hydrophilic arginine-rich
CPPs, particularly R9, becomes more effective when the hydrophobic
counter-anion pyrenebutyrate is present in both experimental set-
ups investigated here. This is seen both in the cellular uptake
experiment where the uptake mechanism is shifted towards direct
cellular penetration and in the splice-switching experimentwhere the
uptake pathway for R9 and translocation of associated ON is shifted
towards endosomal uptake. The combined experiments yield infor-
mation that we have used to delineate potential mechanistic path-
ways for CPP-mediated cellular delivery under varying conditions.
These ﬁndings may also have implication on the development of new
covalently modiﬁed guanidinium-rich CPPs, that will have favorable
properties under in vivo conditions where the opportunity to use
hydrophobic counter-anions is restricted. Such peptides or peptoids
may have applications for drug delivery, in particular for oligonucleo-
tide-based therapeutics.
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